OPHTHALMIC BETA-BLOCKERS - DETERMINATION OF PLASMA AND AQUEOUS-HUMOR LEVELS BY A RADIORECEPTOR ASSAY FOLLOWING MULTIPLE DOSES

被引:16
作者
PHAN, TMM [1 ]
NGUYEN, KPV [1 ]
GIACOMINI, JC [1 ]
LEE, DA [1 ]
机构
[1] UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,100 STEIN PLAZA,LOS ANGELES,CA 90024
来源
JOURNAL OF OCULAR PHARMACOLOGY | 1991年 / 7卷 / 03期
关键词
D O I
10.1089/jop.1991.7.243
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
We determined the binding affinities of multiple doses of four ophthalmic beta-blockers, timolol, betaxolol, levobunolol and carteolol, to the beta-1 and beta-2 receptors. With a K(i) value of 0.39 nM and 0.36 nM for the beta-1 and beta-2 receptors, respectively, levobunolol shows the highest binding affinity to both beta receptors. The K(i) values of timolol (1.97 nM for the beta-1 receptor and 2.00 nM for the beta-2 receptor) and of carteolol (0.83 nM and 0.85 nM for the beta-1 and beta-2 receptors, respectively) are characteristic of a nonspecific beta-blocker. On the contrary, betaxolol is a beta-1 specific antagonist (K(i) of 23.33 nM) and has a very low binding affinity to the beta-2 receptor (K(i) of 200.00 nM). With a radioreceptor assay, levels of beta-antagonist were measured in the plasma and aqueous humor 1 hour and 12 hours after instillation of 50-mu-l of 0.5% or 2% each of the four beta-blockers into the rabbit eye. At 1 hour after administration, the plasma levels of timolol, levobunolol, and carteolol are 9.89 ng/ml, 1.60 ng/ml and 8.00 ng/ml, respectively; such levels of 11.82 to 29.22 times the respective K(i) values cause a virtually total blockade of both beta-1 and beta-2 receptors and suggest significant systemic absorption. Betaxolol has a peak 1 hour plasma level of 22.28 ng/ml, which is equivalent to only 3.08 times its K(i) for the beta-1 receptor and 0.36 times its K(i) for the beta-2 receptor; it has less systemic beta-1 blocking activity than the other three drugs and very minimal systemic beta-2 blocking activity. Peak aqueous humor concentrations of all 4 beta-blockers are extremely elevated at 1 hour after administration (timolol 1613.58 ng/ml; betaxolol 866.06 ng/ml; levobunolol 750.89 ng/ml; and carteolol 859.18 ng/ml). Such levels of 14 to 7192 times the respective K(i) values should cause a virtually complete blockade of both beta-1 and beta-2 receptors in the iris-ciliary body complex. At 12 hours after administration, plasma levels of all four beta blockers remain moderately elevated (timolol 0.94 ng/ml; betaxolol 9.43 ng/ml; levobunolol 0.66 ng/ml; and carteolol 1.61 ng/ml). Trough aqueous humor levels of levobunolol (43.38 ng/ml) and carteolol (92.81 ng/ml) remain elevated at least 300 times their K(i) value. On the contrary, 12-hour trough aqueous humor levels of timolol (33.67 ng/ml) and betaxolol (94.86 ng/ml) have decreased to 2 to 40 times their K(i) value, which may explain their requirement for twice daily administration clinically.
引用
收藏
页码:243 / 252
页数:10
相关论文
共 36 条
[1]  
Zimmerman T.J., Kaufman H.E., Timolol, a beta-adrenergic blocking agent for the treatment of glaucoma, Arch. Ophthalmol, 95, pp. 601-604, (1977)
[2]  
Zimmerman T.J., Harbin R., Pett M., Et al., Timolol and facility of outflow, Invest. Ophthalmol. Vis. Sci, 16, pp. 623-624, (1977)
[3]  
Duff G.R., Graham P.A., A double cross-over trial comparing the effects of carteolol and placebo on intraocular pressure, Br. J. Ophthalmol, 72, pp. 27-28, (1988)
[4]  
Levy N.S., Boone P.A., Ellis E., A controlled comparison of betaxolol and timolol with long-term evaluation of safety and efficacy, Glaucoma, 7, pp. 54-62, (1985)
[5]  
Stewart R.H., Kimbrough R.L., Ward R.L., Betaxolol vs timolol: a six-month double-blind comparison, Arch. Ophthalmol, 104, pp. 46-48, (1986)
[6]  
Berry D.P., Van Buskirk E.M., Shields M.B., Betaxolol vs timolol: a comparison of efficacy and side effects, Arch. Ophthalmol, 102, pp. 42-45, (1984)
[7]  
Allen R.C., Hertzman E., Walker A.M., Epstein D.L., A double-masked comparison of betaxolol vs. timolol in the treatment of open-angle glaucoma, Am. J. Ophthalmol, 101, pp. 535-541, (1986)
[8]  
Berson F.B., Cohen H.B., Foerster R.J., Lass J.H., Novack G.D., Duzman E., Levobunolol compared with timolol for the long-term control of elevated intraocular pressure, Arch. Ophthalmol, 103, pp. 379-382, (1985)
[9]  
Cinotti A., Cinotti D., Grant W., Jacobs, I., Galin, M., et al. Levobunoloi vs timolol for open-angle glaucoma and ocular hypertension, Am. J. Ophthalmol, 99, pp. 11-17, (1985)
[10]  
Levobunolol: a beta-adrenoreceptor antagonist effective in the long-term treatment of glaucoma, Ophthalmol, 92, pp. 1271-1276, (1985)